For instance, individuals carrying the UGT2B17 deletion have been described to show both significantly reduced overall glucuronidation rates of nicotine and its major metabolites in smokers [37] and of androgen substrates in prostate cancer patients [38]. Here, UGT2B17 is linked to prostate carcinoma.